Introduction
Carbonyl reduction into the alcohol metabolites is an important Phase-I metabolism of carbonyl-containing drugs, which include more than 30 pharmacologically relevant drugs (Hoffmann and Maser, 2007; Barski et al., 2008) . Various carbonyl compounds in the environment also enter the body as xenobiotics and environmental pollutants. In addition, many endogenous carbonyl compounds are formed through metabolisms of biogenic amines, steroids, prostaglandins (PGs) and sugars, lipid peroxidation and glycation. To excrete and detoxify the chemically divergent carbonyl compounds, several NADPH-dependent reductases with broad substrate specificity for carbonyl compounds exist in the body. The enzymes with known primary structures are grouped into two distinct protein families: the short-chain dehydrogenase/reductase (SDR) (Hoffmann and Maser, 2007) and aldo-keto reductase (AKR) (Barski et al., 2008; Jin and Penning, 2007) superfamilies. Although fifteen of such carbonyl-reducing enzymes are known in humans (Matsunaga et al., 2006; Oppermann, 2007) , major enzymes responsible for the reduction of drug ketones are carbonyl reductase (CBR) and 11β-hydroxysteroid dehydrogenase (HSD) type 1 in the SDR superfamily (Hoffmann and Maser, 2007) , and those belonging to the AKR superfamily are cytosolic HSD isoforms (AKR1C1, AKR1C2, AKR1C3 and AKR1C4) (Barski et al., 2008; Matsunaga et al., 2006) , as well as aldehyde reductase, aldose reductase, aldose reductase-like protein (AKR1B10) and/or aflatoxin reductase that reduce daunorubicin and doxorubicin (Bains et al., 2010) . AKR1B10, AKR1C1 and AKR1C3 are suggested to be involved in proliferation of several types of cancer, and their selective inhibitors are expected to be useful for cancer treatments (El-Kabbani et al., 2011; Byrns et al., 2011; Matsunaga et al., 2013) .
In laboratory animal rats or mice, five AKRs similar to the human HSD isoforms have been suggested to reduce xenobiotic carbonyl compounds (Matsunaga et al., 2006; Ishikura et al., 2006a; 2006b) , but their reactivity towards drug ketones has been scarcely studied. In contrast, rabbit reductases for several drug ketones were studied, since they had been reported to be as a class of drug metabolizing enzymes (Bachur, 1976) and extremely active carbonyl-drug reduction potential was found in rabbit liver cytosol (Ahmed et al., 1978；1979) .
The studies on reductases for daunorubicin, oxisuran, metyrapone and naloxone indicate that each reductase exists in multiple forms in the liver cytosol (Ahmed et al., 1978；1979; Sawada and Hara, 1979; Felsted et al., 1980) . Subsequently, two of four multiple forms of rabbit naloxone reductase (NR1 and NR2) were shown to belong to the AKR superfamily by their partial protein sequencing, and differ from each other in their stereospecific reduction of the drug and substrate specificity for naltrexone and 3/17-hydroxysteroids (Yamano et al., 1999) .
A major form of four loxoprofen reductases (LRs) in rabbit liver cytosol also shows 3-and 17-ketosteroid reductase activity (Tanaka et al., 1989) . The presence of multiple forms of befunolol reductase in rabbit liver cytosol was also reported, although one form was identified as CBR (Imamura et al., 1989) . However, in addition to the properties of the other multiple forms, the entire primary sequences of the enzymes other than CBR (Gonzalez et al., 1995) have not been studied, and the interrelationship among the enzymes remains unknown.
Recently, recombinant rabbit 20α-HSD (AKR1C5) and 3-hydroxyhexobarbital dehydrogenase (AKR1C29) have been reported to exhibit NADPH-linked reductase activity towards several drug ketones. AKR1C5 reduces xenobiotic carbonyl compounds including befunolol and ketotifen, although it is expressed specifically in rabbit ovary and uterus (Endo et al., 2013a) . AKR1C29 ubiquitously expressed in rabbit tissues reduces befunolol, daunorubicin, naloxone and loxoprofen, as well as endogenous substrates such as 3-, 17-and 20-ketosteroids and PGD 2 (Endo et al., 2013c) . However, the properties and/or amino acid sequences of AKR1C5 and AKR1C29 are different from those of NR1 and NR2, and the major form of LR. Current rabbit genomic analysis has predicted four genes encoding the AKR1C subfamily proteins that share high sequence identity with the partial sequences of predicted from the rabbit genomic analysis, and their sequences and PCR conditions are summarized in Supplemental Table 1 . The PCR products of the cDNAs for AKR1C30, AKR1C31 and AKR1C32 were purified, digested with the two restriction enzymes (Life Technologies, Carlsbad, CA), and ligated into the pCold I vectors (Takara Bio Inc., Otsu, Japan) that had been digested with the restriction enzymes (Endo et al., 2012a) . The PCR product of AKR1C33 cDNA was purified, and ligated into the pGEX-2T vectors (GE healthcare UK Ltd., Buckinghamshire, England) as described (Matsuura et al., 1998) . The inserts of the cloned cDNAs were sequenced by using a Beckman CEQ8000XL DNA sequencer, and were confirmed to encode the 322-amino acid sequence of AKR1C33 and 323-amino acid sequences of the other AKRs (1C30, 1C31 and 1C32) fused to the N-terminal 6-His tag. The sequences of cDNAs for AKR1C30, AKR1C31, AKR1C32 and AKR1C33
were deposited in DDBJ database with the accession numbers AB854079, AB854080, AB854081 and AB854082, respectively.
In the RT-PCR analysis of the expression of mRNAs for the four AKRs in rabbit tissues, the preparation of total RNA samples, RT and PCR were carried out as described above. The cDNA for rabbit β -actin was also amplified as an internal control with primers (Supplemental Table 1 ). The PCR products were separated by agarose gel electrophoresis, and revealed with ethidium bromide.
Expression and Purification of Recombinant Enzymes. The recombinant AKR1C30,
AKR1C31 and AKR1C32 were expressed in Escherichia coli BL21 (DE3) pLysS cells transformed with the expression plasmids harboring their cDNAs as described previously (Endo et al., 2012a) . The enzymes were purified from the cell extracts using a nickel-charged Sepharose 6FF resin (GE Healthcare, Chalfont St Giles, UK) according to the manufacturer's protocol. The enzyme fraction was concentrated by ultrafiltration and dialyzed against 10-mM
Tris-HCl buffer, pH 8.0, containing 5-mM 2-mercaptoethanol, 0.5-mM EDTA and 20% (v/v) glycerol. The recombinant AKR1C33 was expressed in E. coli BL21 (DE3) pLysS and purified by the methods for purification of AKR1C1 (Matsuura et al., 1998) . Purity was confirmed by SDS-polyacrylamide gel electrophoresis, and protein concentration was determined by Bradford's method using bovine serum albumin as the standard (Sambrook et al.,1989) .
Assay of Enzyme Activity. The reductase activities for the enzymes were assayed by measuring the rate of change in absorbance (at 340 nm) of NAD(P)H. The corresponding standard reaction mixture consisted of 0.1-M potassium phosphate buffer, pH 7.4, 0.1-mM NADPH or NADH, substrate and enzyme, in a total volume of 2.0 ml. The assay of all-trans-retinal reductase activity was performed according to the method of Parés and Julià Product Identification. The reaction was conducted at 37 ºC in a 2.0-ml reaction mixture, containing 0.1-mM NADPH, substrate (0.02 -0.1 mM), enzyme (0.1 mg), and 0.1-M potassium phosphate, pH 7.4. The substrate and products were extracted into 4-ml ethyl acetate 20 min after the reaction was started. The products of oxidoreduction of steroids (Ishikura et al., 2006b; Endo et al., 2012a) and reduction of PGD 2 (Watanabe et al., 1986) , drug ketones (Ohara et al., 1995) and 4-oxo-2-nonenal (Doorn et al., 2003) were analyzed by TLC. The products in the reduction of 5α-androstan-17β-ol-3-one were identified by liquid chromatography/mass spectrometry using a Chiralcel OJ-H 5 μ m column (Ishikura et al., 2006b ). (Fig. 1) . In contrast, the three enzymes showed lower sequence identity (73-77%) with AKR1C33.
The sequence of AKR1C30 was identical to the partial sequence (composed of a total 316 residues) of rabbit liver NR1 (Yamano et al., 1999) , with the exception of a four residue difference at positions 80, 248, 267 and 310. The partial sequence (composed of a total 215 residues) of rabbit liver NR2 also matched the AKR1C33 sequence, with the exception of an 8-amino acid difference. AKR1C30, AKR1C31 and AKR1C32 shared high sequence identity (80-91%) with other rabbit members of the AKR1C subfamily (AKRs: 1C5, 1C26, 1C27, 1C28 and 1C29) (Lacy et al., 1993; Endo, et al., 2013a; 2013c) , of which rabbit 20α-HSD (AKR1C5) exhibited the highest sequence identity (91%) with AKR1C32. AKR1C33 showed lower sequence identity (73-77%) with the other rabbit members of the AKR1C subfamily.
The present four AKRs share the highest sequence identity with four human AKRs (1C1, 1C2, 1C3 and 1C4; 74-80%) among the known extra-rabbit members of the AKR1C subfamily. Naloxone was reduced by AKR1C30, AKR1C32 and AKR1C33, of which AKR1C30 and AKR1C33 showed the highest k cat and lowest K m values, respectively. The reduced products of naloxone by AKR1C30 and AKR1C33 were identified as 6α-naloxol and 6β-naloxol, respectively, by TLC, whereas both 6α-and 6β-naloxols were detected as the reduced products by AKR1C32. Naltrexone was reduced only by AKR1C33, and 6β-naltrexol was detected as the reduced product. The reactivity and stereoselective reduction of AKR1C30 and AKR1C33 are almost identical to those of NR1 and NR2, respectively (Yamano et al., 1999) .
Among other drug ketones, daunorubicin and befunolol were reduced by all the enzymes, of The four enzymes also reduced xenobiotic other ketones, p-quinones and aromatic aldehydes, and showed some differences in their kinetic constants (Table 2) Substrate Specificity for Ketosteroids. All the enzymes reduced ketosteroids, but showed significant differences in the specificity (Table 4) . AKR1C30 reduced only etiocholanolone (5β-androstan-3α-ol-17-one) and 5β-androstane-3,17-dione into their 17β-hydroxyl metabolites. The other enzymes were active towards 3-, 17-and 20-ketosteroids, but differed in the reactivity with respect to the configuration of the A and B rings of the steroid molecules, in which the ring fusion in 5α-and 5β-dihydrosteroids are of the trans-type and cis-type, respectively. Among the three enzymes, AKR1C31 showed the narrowest substrate specificity for 3-keto-5α-dihydrosteroids and 20-keto-5β-pregnanes. As the identified products in the reduction of the ketosteroids are summarized in Fig. 2 , AKR1C31 three 5α-dihydrosteroids [5α-dihydrotestosterone (5α-androstan-17β-ol-3-one), 5α-pregnan-20α-ol-3-one and 5α-androstane-3,17-dione] into their 3α-hydroxyl metabolites, and exhibited reductive 20α-HSD activity only towards 5β-pregnan-3α-ol-20-one and 5β-pregnane-3,20-dione. In the reduction of 17-ketosteroids, AKR1C31 reduced 5β-androstans (etiocholanolone and 5β-androstane-3,17-dione) and 4-androstene-3,17-dione.
AKR1C32 was similar to AKR1C31 in the reductive 17β-HSD activity towards 17-keto-5β-androstanes, but differed from AKR1C31 in its broad specificity for both 5α-and 5β-dihydrosteroids in the reductive 3α-HSD activity and strict specificity for 5α-pregnanes in the reduction of the 20-keto group. AKR1C32 did not exhibit significant activity for 5β-pregnan-3α-ol-20-one, and the reduced product of 5β-pregnane-3,20-dione by the enzyme was identified as its 3α-hydroxyl metabolite, indicating that the enzyme predominantly reduced the 3-keto group on 5β-pregnanes. AKR1C33 showed the broadest steroid specificity among the enzymes. It reduced not only 3-, 17-and 20-ketosteroids listed in Table 4 , but also
3-keto-bile acids, 7α-hydroxy-5β-cholestan-3-one, 7α,12α-dihydroxy-5β-cholestan-3-one, 5α/β-androstan-3β-ol-17-ones and estrone that were not reduced by the other enzymes (Table   5 ). The reduced products of 5α/β-androstane-3,17-diones and 5α/β-pregnane-3,20-diones were their 17β-hydroxyl and 20α-hydroxyl metabolites, respectively (Fig. 2) . Thus, AKR1C33
exclusively acted as reductive 17β-or 20α-HSD towards the above diketosteroids, although it reduced 3-ketosteroids without keto groups at position 17 or 20. The K m values of the three AKRs (1C31, 1C32 and 1C33) for most steroidal substrates were in the micromolar or submicromolar range, and their k cat /K m values were comparable to those for good non-steroidal substrates (isatin, p-quinones and long-chain alkenals). Especially, the k cat /K m values of AKR1C33 for 5α-androstane-3,17-dione, 5α-androstan-3β-ol-17-one, 3-keto-bile acids and 3-keto-5β-cholestanes were higher than those of the other enzymes for ketosteroids.
Substrate Specificity for Alcohols. In the NADP + -linked reverse reaction, the four AKRs oxidized nonsteroidal alcohols, of which β -ionol [4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-ol] was the most efficient substrate for each enzyme (Table 6 ). Although AKR1C33 oxidized farnesol, an aliphatic alcohol, with a low K m value, it exhibited higher K m values for alicyclic alcohols (S-1-tetralol, 1-acenaphthenol, S-1-indanol and trans-benzene dihydrodiol)
than the other enzymes. In the oxidation of hydroxysteroids, AKR1C33 efficiently oxidized various 3α-, 17β-and 20α-hydroxysteroids including conjugated bile acids, which are major biliary bile acids of rabbits (Hagey et al., 1998) (Tables 4 and 5 ). In contrast, the other enzymes did not exhibit significant activity towards the 3α-hydroxysteroids. AKR1C30
showed dehydrogenase activities only towards 17β-hydroxy-5β-androstanes, whereas AKR1C31 and AKR1C32 oxidized some 17β-hydroxysteroids and 20α-hydroxy-5α/β-pregnanes with higher K m values compared to those in the reduction of 20-ketosteroids. It should be noted that all the four enzymes did not oxidize 3β-hydroxysteroids (5α/β-androstan-3β-ol-17-ones, 5α/β-pregnan-3β-ol-20-ones and
isolithocholic acid), 17α-hydroxysteroids (4-androsten-17α-ol-3-one and 17α-estradiol) and 20β-hydroxysteroids (4-pregnene-17α,20β-diol-3-one and 5α-pregnan-20β-ol-3-one).
Inhibitor Sensitivity. The inhibitor sensitivities of the four AKRs were compared by examining effects of various compounds on dehydrogenase activities towards 5α-androstane-3α,17β-diol (for AKR1C33) and β -ionol (for the other enzymes), which were efficient substrates of the enzymes. The inhibitors were classified based on enzyme selectivity (Table 7) , and their structures are shown in Supplemental Fig. 2 . Among the enzymes, AKR1C30 was selectively inhibited by an 11β-HSD inhibitor, carbenoxolone (Gomez-Samchez and Gomez-Samchez, 1992), and aldehyde reductase inhibitors, valproic acid and phenobarbital (Kanazu et al., 1991) . Glycyrrhetinic acid, a des-carboxypropanoyloxy derivative of carbenoxolone, showed less inhibitory potency (IC 50 =18 μ M), and other aldehyde reductase inhibitors, barbital and diphenic acid (each 1 mM), did not inhibit this enzyme. AKR1C31 was highly sensitive to baccharin, a human 17β-HSD type 5 (AKR1C3)
inhibitor (Endo et al., 2012b) , and 7-hydroxyflavone. AKR1C32 was most potently inhibited by phenolphthalein and hinokitiol (2-hydroxy-6-propan-2-ylcyclohepta-2,4,6-trien-1-one), which are known as inhibitors of rabbit 20α-HSD (AKR1C5) (Endo et al., 2013a) and NAD + -dependent 3α/17β-HSD (AKR1C28) (Endo et al., 2013b) . AKR1C33 was inhibited selectively or most potently by synthetic estrogens (hexestrol and diethylstilbestrol), a mycoestrogen (zearalenone) and betamethasone, which are known as inhibitors of NADP(H)-dependent 3α-, 17β-and 20α-HSDs (AKR1C1-1C4) of humans (Higaki, et al., 2003) and rats (Ishikura et al., 2006a) . These selective inhibitors inhibited the enzymes competitively with respect to β -ionol or 5α-androstane-3α,17β-diol, as the inhibition patterns of the representative inhibitors are shown in Fig. 3 . The K i values of the competitive inhibitors are listed in Table 7 . Nonspecific inhibitors included isolithocholic acid, flavonoids (kaempferol and quercetin) and anti-inflammatory flufenamic acid, which showed similar
inhibition to more than two enzymes.
Tissue Distribution. The tissue distributions of AKR1C30, AKR1C31, AKR1C32 and AKR1C33 were assessed by RT-PCR (Fig. 4) . The mRNAs for the four enzymes were detected in almost all rabbit tissues examined, but their expression levels in the tissues differed from one another. The tissue expression patterns of the mRNAs for AKR1C30 and AKR1C31 were similar, although the level of AKR1C31 transcript relative to AKR1C30 was lower in all tissues. The two enzymes were abundantly expressed in the brain, heart, liver, renal cortex, intestine, colon and testis. The mRNA for AKR1C32 was highly expressed in the lung, heart, liver, renal cortex, renal medulla, adrenal gland and testis, and its high expression in the lung and renal medulla and adrenal gland was distinct from those of the other enzymes. AKR1C33 showed the most striking tissue specific expression, in which its levels in the liver and small intestine were much higher than those in the other tissues.
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Discussion
The present study have revealed that, in addition to AKR1C29 (Endo et al., 2013c) , four AKRs (1C30, 1C31, 1C32 and 1C33) with broad substrate specificity are distributed in many rabbit tissues. The differences between the enzymes in their substrate specificity for drug ketones suggest their relationship with the following multiple forms of NADPH-dependent drug ketone reductases that were separated or isolated from rabbit liver cytosol. 1) NR:
AKR1C30 and AKR1C33 are identical to NR1 and NR2, respectively, of four multiple forms of NR (Yamano et al., 1999) , as evidenced by their coinciding sequences, 17β-estradiol coenzyme specificity, stereoselective reduction of naloxone, and substrate specificity for naltrexone and hydroxysteroids. The other two multiple forms of NR may be AKR1C32 and AKR1C29, because of similarities in their dual coenzyme specificity and non-stereoselective reduction of naloxone into both 6α-and 6β-naloxols. 2) LR: AKR1C32 is also identical to the major form of rabbit liver LR (Tanaka et al., 1989) , because its substrate specificity for 3-keto-5α/β-androstanes, 5β-androstan-3α-ol-17-one and adamantanone resembles that of this form of LR. Although the other three multiple forms of rabbit liver LR were not characterized, they may correspond to AKR1C31, AKR1C29 and CBR, which reduce this drug (Endo et al., 2013c; Imamura et al., 1989) . 3) Reductases for befunolol and daunorubicin: Although CBR and/or aldehyde reductase are the major forms of the two drug reductases, further multiple forms distinct from the two enzymes were separated from rabbit liver cytosol (Imamura et al., 1989; Ahmed et al., 1978; Felsted et al., 1980) . The multiplicity of the two drug reductases is probably due to the presence of the four AKRs and AKR1C29, of which AKR1C31 may act as an efficient enzyme because of its conspicuously lower K m values for the two drugs compared to other rabbit enzymes including aldehyde reductase and CBR. 4)
Reductases for other drug ketones: Metyrapone reductase activity in rabbit liver cytosol was separated into three peaks (Ahmed et al., 1979) . Among the five AKRs, AKR1C30 and AKR1C33 reduced metyrapone, and may correspond to two of the multiple forms of the drug reductase. Ketotifen is reduced by AKR1C5 in rabbit ovary and uterus (Endo et al., 2013a) , but in the other tissues only AKR1C30 acts as a reductase for this drug. Fenofibric acid, an active metabolite of fenofibrate, is further metabolized by carbonyl reduction in humans and laboratory animals, and the reduced fenofibric acid metabolite contributes to the hypolipidemic action of this drug (Caldwell, 1989) , but the fenofibric acid reductase has not been reported. AKR1C33 is the first mammalian enzyme that reduces fenofibric acid, suggesting that enzymes in the AKR1C subfamily may be responsible for the pharmacologically significant reduction of this drug in other mammalian species.
In addition to the differences in the reactivity towards the above drug ketones, the present four AKRs differ from one another and AKR1C29 (Endo et al., 2013c) in their kinetic constants for other xenobiotic carbonyl compounds. Thus, one reason of the existence of the five NADPH-dependent AKR1C subfamily enzymes in many rabbit tissues is the elimination of structurally divergent xenobiotic carbonyl compounds by their metabolism into the corresponding less lipophilic alcohols, which are excreted directly or after conjugation by phase-II drug metabolizing enzymes. Like other mammalian NADPH-dependent AKR1C subfamily enzymes (Barski et al., 2008; Jin and Penning, 2007; Matsunaga et al., 2006) , the present four AKRs reduced various endogenous carbonyl compounds, and their specificities for endogenous substrates are also similar to that of AKR1C29 (Endo et al., 2013c) . As described for AKR1C29, the present four AKRs may be involved in the metabolism of PGD 2 , detoxification of reactive lipid-derived aldehydes (4-oxo-and 4-hydroxy-2-nonenals) (Esterbauer et al., 1991) , glycation intermediates (methylglyoxal, glyoxal and of the present other AKRs and known rabbit enzymes: AKR1C5, AKR1C29, rabbit aldose reductase (AKR1B2) and aldose reductase-like protein (AKR1B19) (Endo et al., 2012a; 2013a; 2013c) . AKR1C32 may play a vital role in detoxification of the two glycation intermediates particularly in the lung and renal medulla, in which the expression of other AKR1C subfamily enzymes including AKR1C29 is low.
In rabbits, ovarian AKR1C5 and ubiquitous AKR1C29 have been reported to be reductive 17β/20α-HSD and 3α/17β/20α-HSD, respectively (Endo et al., 2013a; 2013c) . The present four AKRs also exhibit reductive HSD activity, but their steroid specificities are clearly different from one another (Fig. 2 ) and the two known AKRs. The substrates of AKR1C30
were etiocholanolone, a neuroactive steroid (Reddy, 2010) , and 5β-androstane-3,17-dione that is converted to a potent vasorelaxant 5β-dihydrotestosterone (Perusquía and Stallone, 2010).
Considering its ubiquitous distribution including rabbit brain, AKR1C30 could be implicated in controlling the cellular levels of the two active steroids. AKR1C31 acted as reductive 3α-HSD (towards an potent androgen, 5α-dihydrotestosterone) and reductive 17β-HSD (towards etiocholanolone, 5β-androstane-3,17-dione and 4-androstene-3,17-dione). The reduced products of 5α-dihydrotestosterone and 4-androstene-3,17-dione by the enzyme were neuroactive 5α-androstane-3α,17β-diol (Reddy, 2010) catalyzed the 17-keto reduction of 5α-androstane-3,17-dione into 5α-dihydrotestosterone more efficiently than the 3-keto reduction of 5α-dihydrotestosterone. It also reduced 4-androstene-3,17-dione into testosterone more efficiently than AKR1C31 and AKR1C29 (Endo et al., 2013c) . Thus, the enzyme may act as a cellular androgen-forming enzyme. 3)
Formation of estrogens: AKR1C33 catalyzed the oxidoreduction between estrone and 17β-estardiol, and resembles the most acidic form (Enzyme III) of rabbit liver NADP + -dependent 17β-HSDs (Antoun et al., 1986) in its pI value (5.9), strict coenzyme specificity for NADP(H) and substrate specificity for 17β-estardiol, testosterone, etiocholanolone and 5α-androstan-3α-ol-17-one. AKR1C33 also produced an estrogen receptor β ligand, 5α-androstane-3β,17β-diol (Weihua et al., 2002) , by the reduction of 5α-androstan-3β-ol-17-one. In rabbits, AKR1B19 exhibits 3β-HSD activity towards 5α-androstane-3,17-dione (Endo et al., 2012a) . It is likely that AKR1C33 contributes to the cellular synthesis of 5α-androstane-3α,17β-diol from 5α-androstane-3,17-dione, in concert with AKR1B19, as well as 17β-estardiol formation.
In addition to significant differences in substrate specificity for drug ketones and ketoster- positioning of the inhibitor is dictated by the configuration of the residues forming the substrate-binding cavity (Penning 1999; Couture et al., 2004 , El-Kabbani et al., 2011 , Byrns et al., 2011 . AKR1C30, AKR1C31 and AKR1C32 shared high amino acid sequence identity (84-94%), and their distinct substrate specificity and inhibitor sensitivity may result from differences in the substrate-binding residues (positions 54, 128, 306, 308 and 311, Fig. 1 ). The broadest steroid specificity of AKR1C33 and its selective inhibition by estrogen-like inhibitors might be attributed to its unique residues (positions 128, 221, 222, 224, 306, 308, 310 and 311) in the substrate-binding residues. Although further studies will be needed to elucidate the roles of the binding residues, the present study provides the selective inhibitors to each of AKRs (1C30-1C33), which do not inhibit AKR1C29 potently (Endo et al., 2013c) .
The inhibitors can be useful to discriminate between the five AKRs (1C29-1C33) in metabolic studies of carbonyl-containing drugs and xenobiotics in the rabbit.
In summary, we have cloned four rabbit members in the AKR1C subfamily, and elucidated their relationship with the multiple forms of drug ketone reductases previously found in the liver cytosol. The substrate specificity and tissue distribution revealed that the four AKRs participate in the reduction of daunorubicin and befunolol, but differently contribute to the reduction of naloxone, naltrexone, loxoprofen, ketotifen, metyrapone and fenofibric acid. In addition, the substrate specificity for endogenous compounds suggests the roles of the enzymes in the metabolisms of steroids, isoprenoids, isatin and reactive carbonyl compounds.
In particular, AKR1C33 that is highly expressed in the liver and intestine was suggested to play critical roles in both metabolism and synthesis of bile acids. Furthermore, inhibitors selective to the respective AKRs were found and can be useful to discriminate the four AKRs in metabolic studies of new carbonyl-containing drugs in the rabbit. 5β-dihydrotestosterone, 5β-androstan-17β-ol-3-one; testosterone, 4-androsten-17β-ol-3-one;
etiocholanolone, 5β-androstan-3α-ol-17-one; progesterone, 4-pregnene-3,20-dione. *The substrates are 5β-pregnan-20α-ol-3-one and 5β-pregnane-3,20-dione for AKR1C32, and it is 5β-pregnan-20α-ol-3-one for AKR1C33. **The substrates are 5β-pregnan-3α-ol-20-one and 5β-pregnane-3,20-dione. 2-tert-Butyl-1,4-benzoquinone. ). 
